Board Change

RNS Number : 5821N
MyHealthChecked PLC
01 October 2021
 

MyHealthChecked PLC 

("MyHealthChecked" or the "Company")

 

Board Change

 

MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, announces the appointment, as previously announced on 28 June 2021 , of Laura Moore as a Non-Executive Director of the Company with effect from 1 October 2021.

 

Passionate about healthcare throughout her career, Laura brings with her a wealth of consumer brand and strategy experience. Starting her career at a boutique strategy consultancy working directly with the CEO, she then worked at global blue-chips Unilever, L'Oréal and Newell Rubbermaid before working on FMCG clients at digital ventures consultancy Bow & Arrow. She founded Nell Health Limited in July 2017 and was CEO until the business was acquired by MyHealthChecked in July 2021. 

 

Commenting, Laura Moore, said: "Joining the MyHealthChecked board is an exciting opportunity to which I can bring my experience and energy, and to ensure we navigate the changes brought to the testing market by the pandemic. I see big things ahead for the business and feel fortunate to be a part of this next stage of MyHealthChecked's development." 

 

Penny McCormick, Chief Executive Officer of MyHealthChecked PLC , commented: "On behalf of the Board I am delighted to welcome Laura as a Non-Executive Director. Laura has amassed an impressive depth of experience around consumer healthcare, and is a highly knowledgeable and ambitious entrepreneur, with a passion for consumer wellness and positive healthcare. Laura's appointment adds richness to our Board as we continue to evolve to be a progressive and forward-looking entity, and we believe Laura's complementary skillsets and new perspective will greatly enhance MyHealthChecked's team in the achievement of our future plans."

 

The following additional information is provided in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies:

 

Laura Elizabeth Moore (34) is currently or has been a director of the following companies within the previous five years:

 

Current directorships/partnerships

Past directorships/partnerships

None

Bettermi Limited

Nell Health Limited

 

 

Ms Moore holds 10,324,291 ordinary shares in the Company representing 1.37% of the Company's current issued share capital. 

 

Save as set out above, no further information is required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies

 

MyHealthChecked PLC

www.myhealthchecked.com

P enny McCormick , Chief Executive Officer

via Walbrook PR

Gareth Davies, Chief Financial and Operations Officer

 

 

 

SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin

 

 

 

Oberon Capital Ltd (Broker)

Tel: +44 (0)203 179 5344

Mike Seabrook

mikeseabrook@oberoninvestments.com

 

 

Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com

Paul McManus / Alice Woodings

Mob: +44(0)7980 541 893 / +44 (0)7407 804 654

 

 

About MyHealthChecked PLC   ( www.myhealthcheckedplc.com )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests. MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the acquisition of The Genome Store in November 2020. The tests will be made available online and would be viable for over-the-counter purchase. 

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market, with a focus on accessibility at the right price, led by UK-based experts.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAURSARAVUKOAR
UK 100

Latest directors dealings